Holen Sie sich die Stockscreener-App
23.21
1.57%
-0.37
Handel nachbörslich:
23.03
-0.18
-0.78%
Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten
Nurix Therapeutics Inc (NRIX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nurix Therapeutics Inc (NRIX) Institutional Confidence - TradingKey
Nurix Therapeutics Inc (NRIX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nurix Therapeutics Inc (NRIX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nurix Therapeutics Inc (NRIX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NRIX|Nurix Therapeutics Inc|Price:23.380|Chg%:-0.360 - TradingKey
TradingKey - TradingKey
Nurix Therapeutics, Inc. (NRIX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Nurix Therapeutics Inc (NRIX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NRIX: Nurix Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight - GlobeNewswire Inc.
NRIX Maintained by UBS -- Price Target Raised to $31 - GuruFocus
UBS Lifts Nurix Therapeutics Price Target to $31 From $23, Maintains Buy Rating - Moomoo
UBS Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Raises Target Price to $31 - Moomoo
Why Did Nurix Therapeutics (NASDAQ:NRIX) Announce Key Clearance? - Kalkine Media
Nurix closes $700m Roche collaboration for bexobrutideg By Investing.com - Investing.com Nigeria
Nurix closes $700m Roche collaboration for bexobrutideg - Investing.com
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology - The Manila Times
Nurix to Receive $700M Upfront in Roche Bexobrutideg Deal - Stock Titan
Nurix Therapeutics, Inc. (NRIX) stock price, news, quote and history - Yahoo Finance UK
Amova Asset Management Americas Inc. Sells 109,408 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Precision Trading with Nurix Therapeutics Inc. (NRIX) Risk Zones - Stock Traders Daily
How Investors May Respond To Nurix Therapeutics (NRIX) Deepening Losses And Sharply Lower Collaboration Revenue - webull.com
Oppenheimer Maintains Nurix Therapeutics (NRIX) Outperform Recommendation - MSN
Nurix Therapeutics advances CLL therapy with DAYBREAK-CLL-201 study - Traders Union
Nurix Therapeutics (NRIX) soars 16.4%: Is further upside left in the stock? - MSN
Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.87, Implies 42% Upside - TradingView
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Q3 EPS Estimates for Nurix Therapeutics Cut by HC Wainwright - MarketBeat
Sumitomo Mitsui Trust Group Inc. Sells 109,408 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Mizuho Raises Price Target on Nurix Therapeutics to $34 From $30, Keeps Outperform Rating - Moomoo
NRIX Maintained by Mizuho -- Price Target Raised to $34.00 - GuruFocus
Mizuho Forecasts Strong Price Appreciation for Nurix Therapeutics (NASDAQ:NRIX) Stock - MarketBeat
Mizuho Securities Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Raises Target Price to $34 - Moomoo
Nurix stock price target raised to $34 by Mizuho on Roche deal - Investing.com UK
55,138 Shares in Nurix Therapeutics, Inc. $NRIX Acquired by Y Intercept Hong Kong Ltd - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Raised to Sell at Wall Street Zen - MarketBeat
Nurix Therapeutics, Inc. (NRIX) reports Q2 loss, lags revenue estimates - MSN
A Quick Look at Today's Ratings for Nurix Therapeutics(NRIX.US), With a Forecast Between $28 to $40 - Moomoo
MSN Money - MSN
NURIX THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $34 FROM $32 - webull.com
Analysts Offer Insights on Healthcare Companies: TruBridge (TBRG), AbbVie (ABBV) and Nurix Therapeutics (NRIX) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Nurix Therapeutics (NRIX), Johnson & Johnson (JNJ) - The Globe and Mail
NRIX Maintained by HC Wainwright & Co. -- Price Target Raised to $34 - GuruFocus
Enterprise value to EBITDA forward of Nurix Therapeutics, Inc. – NASDAQ:NRIX - TradingView
Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.5, Implies 32% Upside - TradingView
NRIX Maintained by Truist Securities -- Price Target Raised to $34.00 - GuruFocus
RBC Capital Initiates Nurix Therapeutics(NRIX.US) With Buy Rating, Announces Target Price $33 - Moomoo
Nurix stock price target raised to $34 by H.C. Wainwright By Investing.com - Investing.com India
Mizuho raises Nurix stock price target to $34 on Roche deal By Investing.com - Investing.com South Africa
Mizuho raises Nurix stock price target to $34 on Roche deal - Investing.com
Nurix stock price target raised to $34 by H.C. Wainwright - Investing.com UK
Baird reiterates Nurix stock Outperform rating at $33 target - Investing.com UK
Baird reiterates Nurix stock Outperform rating at $33 target By Investing.com - Investing.com Australia
Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.25, Implies 31% Upside - TradingView
Russell Growth Index Additions Could Be A Game Changer For Nurix Therapeutics (NRIX) - Sahm
Nurix Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
NRIX Reiterated by Needham -- Price Target Maintained at $34 - GuruFocus
NRIX Maintained by Stifel -- Price Target Raised to $40 - GuruFocus
NRIX Maintained by RBC Capital -- Price Target Raised to $33 - GuruFocus
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):